Evaluating Newly Approved Drugs for Multidrug-resistant TB

  • STATUS
    Recruiting
  • End date
    Aug 20, 2023
  • participants needed
    750
  • sponsor
    Médecins Sans Frontières, France
Updated on 20 September 2021
vasectomy
fluoroquinolones
linezolid
pyrazinamide
moxifloxacin
levofloxacin
pulmonary tuberculosis
bedaquiline
delamanid
clofazimine

Summary

endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).

Description

This is a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of new combination regimens for MDR-TB treatment.

Regimens examined combine newly approved drugs bedaquiline and/or delamanid with existing drugs known to be active against Mycobacterium tuberculosis (linezolid, clofazimine, moxifloxacin or levofloxacin, and pyrazinamide). The study will enroll in parallel across 5 experimental and 1 standard-of-care control arms. Randomization will be outcome adapted using Bayesian interim analysis of efficacy endpoints. Experimental regimens will contain bedaquiline and/or delamanid and up to 4 companion drugs. Control-arm treatment may contain one of the following (bedaquiline or delamanid) and companion drugs, constructed and delivered according to local standard of care and consistent with WHO guidelines. Trial participation in all arms will last at least until Week 73, and up to Week 104. In the experimental arms, treatment will be for 39 weeks (participants in the experimental arms will be allowed up to 47 weeks to complete the 39-week treatment course) and post-treatment follow up for up to 65 additional weeks. In the control arm, treatment will be delivered according to local standard of care (in consistence with WHO guidance); duration may vary and will be approximately 86 weeks for the conventional regimen and 39-52 weeks for the standardized shorter regimen.

Non-inferiority will be established for any experimental arm if the lower bound of the one-sided 97.5% confidence interval around the difference in favorable outcome between the control and experimental arms is greater than or equal to -12%.

Details
Condition Pulmonary Disease, Bacterial Infection, drug-resistant tuberculosis, Pulmonary tuberculosis, Lung Disease, Bacterial Infections, bacterial disease
Treatment pyrazinamide, moxifloxacin, levofloxacin, bedaquiline, delamanid, linezolid, Clofazimine, Control arm MDR-TB regimen, consistent with WHO guidelines
Clinical Study IdentifierNCT02754765
SponsorMédecins Sans Frontières, France
Last Modified on20 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

A patient will be eligible for randomization if s/he
Has documented pulmonary tuberculosis due to strains of M. tuberculosis resistant to rifampin (RIF) and susceptible to fluoroquinolones, diagnosed by validated rapid molecular test
Is 15 years of age
Is willing to use contraception: pre-menopausal women or women whose last menstrual period was within the preceding year, who have not been sterilized must agree to use contraception unless their partner has had a vasectomy; men who have not had a vasectomy must agree to use condoms
Provides informed consent for study participation; additionally a legal representative of patients considered minor per local laws should also provide consent
Lives in a dwelling that can be located by study staff and expects to remain in the area for the duration of the study

Exclusion Criteria

A patient will not be eligible for randomization if s/he
Has known allergies or hypersensitivity to any of the investigational drugs
Is known to be pregnant or is unwilling or unable to stop breast-feeding an infant
Is unable to comply with treatment or follow-up schedule
Any condition (social or medical) which, in the opinion of the site principal investigator, would make study participant unsafe
a. Has had exposure (intake of the drug for 30 days or more) in the past five years to bedaquiline, delamanid, linezolid, or clofazimine, or has proven or likely resistance to bedaquiline, delamanid, linezolid, or clofazimine (e.g., household contact of a DR-TB index case who died or experienced treatment failure after treatment containing bedaquiline, delamanid, linezolid, or clofazimine or had resistance to one of the listed drugs); exposure to other anti-TB drugs is not a reason for exclusion
Has received second-line drugs for 15 days or more prior to screening visit date in the current MDR/RR-TB treatment episode. Exceptions include: (1) patients whose treatment has failed according to the WHO definition151 and who are being considered for a new treatment regimen; (2) patients starting a new treatment regimen after having been "lost to follow-up" according to the WHO definition149 and, (3) patients in whom treatment failure is suspected (but not confirmed according to WHO definition), who are being considered for a new treatment regimen, and for whom the Clinical Advisory Committee (CAC) consultation establishes eligibility
Has one or more of the following
Hemoglobin 7.9 g/dL
Uncorrectable electrolytes disorders
Calcium < 7.0 mg/dL
Potassium < 3.0 or 6.0 mEq/L
Magnesium < 0.9 mEq/L
Serum creatinine > 3 x ULN
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) 3 x ULN
Total bilirubin 1.5 x ULN if accompanied by AST or ALT > ULN or total bilirubin 2 x ULN when other liver function results are in the normal range
Grade 4 result on any of the specified laboratory tests as defined by the MSF Severity Scale
Has cardiac risk factors defined as
A confirmed QTc interval of greater than or equal to 450 ms. Retesting to reassess eligibility will be allowed once using an unscheduled visit during the screening phase
Evidence of ventricular pre-excitation (e.g., Wolff Parkinson White syndrome)
Electrocardiographic evidence of either
Complete left bundle branch block or right bundle branch block; OR
Incomplete left bundle branch block or right bundle branch block and QRS complex duration greater or equal to 120 msec on at least one ECG
Having a pacemaker implant
Congestive heart failure
Evidence of second or third degree heart block
Bradycardia as defined by sinus rate less than 50 bpm
Personal or family history of Long QT Syndrome
Personal history of arrhythmic cardiac disease, with the exception of sinus arrhythmia
Personal history of syncope (i.e. cardiac syncope not including syncope due to vasovagal or epileptic causes)
Concurrent participation in another trial of any medication used or being studied for TB treatment, as defined in cited documents
Is taking any medication that is contraindicated with the medicines in the trial regimen which cannot be stopped (with or without replacement) or requires a wash-out period longer than 2 weeks
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note